Michael D. Shapiro, DO; Joshua Miles, BS; Hagai Tavori, PhD; Sergio Fazio, MD, PhD
Acknowledgment: The authors thank Paul Ziajka, MD, for contributing plasma samples for 1 of the participants.
Grant Support: Partially supported by National Institutes of Health (National Heart, Lung, and Blood Institute) R01 grant HL-132985 (Dr. Fazio).
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2485.
Reproducible Research Statement:Study protocol and statistical code: Not available. Data set: Available from Dr. Shapiro (e-mail, email@example.com).
Shapiro MD, Miles J, Tavori H, et al. Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. Ann Intern Med. 2018;168:376–379. [Epub ahead of print 28 November 2017]. doi: https://doi.org/10.7326/M17-2485
Download citation file:
Published: Ann Intern Med. 2018;168(5):376-379.
Published at www.annals.org on 28 November 2017
Cardiology, Coronary Risk Factors, Dyslipidemia.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use